Pemirolast Monograph for Professionals - Drugs.com

Skip to main content
Print
Save

# Pemirolast

Brand name: Alamast
Drug class: Antiallergic Agents
VA class: OP300
Chemical name: 9-Methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2a]pyrimidin-4-one potassium salt
Molecular formula: C10H7KN6O
CAS number: 100299-08-9

Medically reviewed by Drugs.com on Aug 22, 2022. Written by ASHP.

## Introduction

Mast-cell stabilizer.

## Uses for Pemirolast

### Allergic Conjunctivitis

Prevention of ocular itching associated with allergic conjunctivitis.

## Pemirolast Dosage and Administration

### Administration

#### Ophthalmic Administration

Apply topically to the eye as an ophthalmic solution. Not for injection or oral use.

Avoid contamination of the solution container.

### Dosage

Available as pemirolast potassium; dosage expressed in terms of the salt.

Initiate therapy before and continue throughout pollen season.

#### Pediatric Patients

##### Allergic Conjunctivitis

###### Ophthalmic

Children ≥3 years of age: 1 or 2 drops of a 0.1% solution in the affected eye(s) 4 times daily.

Symptomatic response (i.e., decreased itching) may be evident within a few days following initiation but frequently requires up to 4 weeks of therapy.

#### Adults

##### Allergic Conjunctivitis

###### Ophthalmic

1 or 2 drops of a 0.1% solution in the affected eye(s) 4 times daily.

Symptomatic response (i.e., decreased itching) may be evident within a few days following initiation but frequently requires up to 4 weeks of therapy.

Detailed Pemirolast ophthalmic dosage information

## Cautions for Pemirolast

### Contraindications

- Known hypersensitivity to pemirolast or any ingredient in the formulation.

### Warnings/Precautions

#### Specific Populations

##### Pregnancy

Category C.

##### Lactation

Distributed into milk in rats; not known whether distributed into human milk. Caution if used in nursing women.

##### Pediatric Use

Safety and efficacy not established in children <3 years of age.

### Common Adverse Effects

Headache, rhinitis, cold/flu symptoms.

## Interactions for Pemirolast

No formal drug interaction studies to date.

## Pemirolast Pharmacokinetics

### Absorption

#### Bioavailability

Following topical application to both eyes (0.1% solution 4 times daily for 2 weeks), peak plasma concentrations were attained within about 25 minutes, but were substantially lower than those following a single (10 mg) oral dose.

### Elimination

#### Elimination Route

10–15% of topical ophthalmic dose excreted unchanged in urine.

#### Half-life

About 4.5 hours.

## Stability

### Storage

#### Ophthalmic

##### Solution

15–25°C.

## Actions

- Suppresses the release of mediators from cells involved in hypersensitivity reactions, including mast cells, and decreases chemotaxis and activation of eosinophils.

- Reportedly blocks calcium channels in mast cell membranes.

## Advice to Patients

- Importance of learning and adhering to proper administration techniques to avoid contamination of the product.

- Importance of removing soft contact lenses prior to administration of each dose. Delay reinsertion for 10 minutes after administration if eyes are not red; do not wear contact lenses if eye(s) are red. Not indicated for contact lens-related irritation.

- Importance of reporting any worsening of symptoms or new-onset ocular pain/discomfort.

- Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.

- Importance of informing patients of other important precautionary information. (See Cautions.)

## Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Pemirolast Potassium
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Ophthalmic | Solution | 0.1% | Alamast (with lauralkonium chloride) | Vistakon

AHFS DI Essentials™. © Copyright 2023, Selected Revisions September 1, 2005. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

Reload page with references included

## More about pemirolast ophthalmic

- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: ophthalmic antihistamines and decongestants
- Breastfeeding

### Patient resources

- Advanced Reading

### Related treatment guides

- Conjunctivitis, Allergic
- Eye Redness/Itching

Medical Disclaimer